Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis

Carcinogenesis

Volumn 28, Issue 11, 2007, Pages 2398-2403

  Iida, Katsuyuki ^a   Itoh, Ken ^a   Maher, Jonathan M ^a   Kumagai, Yoshito ^b   Oyasu, Ryoichi ^c   Mori, Yukio ^d   Shimazui, Toru ^a   Akaza, Hideyuki ^a   Yamamoto, Masayuki ^a  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A6; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DETOXIFICATION; GENE DISRUPTION; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINE LEVEL; WILD TYPE;

ANIMALS; BASE SEQUENCE; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; DNA PRIMERS; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; MUTATION; NF-E2-RELATED FACTOR 2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 36148977625     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm146     Document Type: Article

References (34)

1. Druckrey,H. et al. (1967) Organotropic carcinogenic effects of 65 various N-nitroso-compounds on BD rats. Z. Krebsforsch., 69, 103-201.
2. IARC. (1978) N-nitrosodi-n-butylamine. IARC Monogr. Eval. Carcinog. Risk Chem. Man, 17, 51-75.
3. Okada,M. et al. (1977) Metabolic fate of N-n-butyl-N (4-hydroxybutyl)- introsamine and its analogues. Selective induction of urinary bladder tumours in the rat. Xenobiotica, 7, 11-24.
4. Ito,N. et al. (1969) Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann, 60, 401-410.
5. Bonfanti,M. et al. (1988) Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res., 48, 3666-3669.
6. Airoldi,L. et al. (1994) Detection of O6-butyl- and O6-(4-hydroxybutyl)-guanine in urothelial and hepatic DNA of rats given the bladder carcinogen N-nitrosobutyl (4-hydroxybutyl) amine. Carcinogenesis, 10, 2297-2301.
7. Hashimoto,Y et al. (1974) In vitro neoplastic transformation of epithelial cells of rat urinary bladder by nitrosamines. Nature 252, 497-499.
8. Iida,K. et al. (2004) Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res., 64, 6424-6431.
9. Hollstein,M. et al. (1991) p53 mutations in human cancers. Science, 253, 49-53.
10. Olivier,M. et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19 607-614.
11. Esrig,D. et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331, 1259-1264.
12. Sarkis,A.S. et al. (1993) Detection of p53 mutations in superficial (T1) bladder carcinomas as a marker of disease progression. J. Natl. Cancer Inst., 85, 53-59.
13. Cheng,J. et al. (2003) Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res., 63, 179-185.
14. Spruck,C.H.III et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54, 784-788.
15. Ozaki,K et al. (1998) High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res., 58, 3806-3811.
16. Nioi,P. et al. (1993) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:qUinone oxidoreductase 1 gene: Reassessment of the ARE consensus sequence. Biochem. J., 374, 337-348.
17. Wasserman, W.W. et al. (1997) Functional antioxidant responsive elements. Proc. Natl Acad. Sci. USA, 94, 5361-5366.
18. Rushtnore,T.H. et al. (1991) The antioxidant responsive element. J. Biol. Chem., 266, 11632-11639.
19. Itoh,K. et al. (1995) Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol., 15, 4184-4193.
20. Moi,P. et al. (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl Acad. Sci. USA, 91, 9926-9930.
21. Venugopal,R. et al. (1996) Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:qUinone oxidoreductase1 gene. Proc. Natl Acad. Sci. USA, 93, 14960-14965.
22. Itoh,K. et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 236, 313-322.
23. Okada,M. et al. (1978) Syntheses of N-alkyl-N (omega-carboxyalkyl)nitrosamines related to N-butyl-N (3-carboxypropyl)nitrosamine, principal urinary metabolite of a potent bladder carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine. Chem. Pharm. Bull., 26, 3909-3913.
24. Oyasu,R. et al. (1978) Induction of tumors in heterotopic bladder by topical application of N-methyl-N-nitrosourea and N butyl-N-(3-carboxypropyl) nitrosamine. Cancer Res., 38 3019-3025.
25. Enomoto,A. et al. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression, of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 59, 169-177.
26. Asher,G. et al. (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl Acad. Sci. USA, 98, 1188-1193.
27. Kumagai,Y. et al. (1994) Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol. Pharmacol., 45, 359-365.
28. Sablina,A.A., et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat. Med., 11, 1306-1313.
29. Schottenfeld,D., et al. (2006) Chronic inflammation: A common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 56, 69-93.
30. Klaunig,J.E. et al. (2004) The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 44, 239-267.
31. Enoch,T. et al. (1995) Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci., 20, 426-430.
32. Faraonio,R. et al. (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J. Biol. Chem., 281, 39776-39784.
33. Yuan,Z.M. et al. (1998) Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene 16, 1643-1648.
34. Li,B. et al. (2004) Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 18, 1824-1837.